Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 3b/4 study titled ‘SWITCH-UP’ to evaluate the efficacy and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab. This study is significant as it aims to provide alternative treatment options for patients with limited responses to existing therapies.
The study tests two interventions: upadacitinib, an oral tablet, and dupilumab, a subcutaneous injection. Upadacitinib is already approved for treating moderate-to-severe atopic dermatitis, and this study seeks to explore its effectiveness in patients who have not responded well to dupilumab.
The study design is interventional, with a randomized allocation and a sequential intervention model. It is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, aiming to assess the therapeutic potential of upadacitinib.
The study began on June 12, 2024, with primary completion expected in the future. The last update was submitted on June 25, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This clinical study update could positively impact AbbVie’s stock performance by showcasing its commitment to addressing unmet medical needs in dermatology. Investors may view this as a strategic move to strengthen AbbVie’s position in the competitive market for atopic dermatitis treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.